For the year ending 2025-12-31, TPST had -$22,561K decrease in cash & cash equivalents over the period. -$26,820K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -26,262 |
| Depreciation expense | 266 |
| Stock-based compensation expense | 3,118 |
| Noncash lease expense | 1,103 |
| Noncash interest and other expense, net | 85 |
| Prepaid expenses and other assets | -615 |
| Accounts payable | -1,412 |
| Accrued expenses and other liabilities | -3,404 |
| Interest payable | -59 |
| Operating lease liabilities | -870 |
| Cash used in operating activities | -26,820 |
| Purchase of property and equipment | 0 |
| Cash used in investing activities | 0 |
| Proceeds from the issuance of common stock, net of issuance costs | 6,045 |
| Proceeds from the issuance of pre-funded warrants, net of issuance costs | 3,309 |
| Proceeds from the issuance of common stock warrants, net of issuance costs | 1,284 |
| Repayment of loan | 6,426 |
| Proceeds from the issuance of common stock under equity plan awards | 47 |
| Cash provided by financing activities | 4,259 |
| Net increase in cash and cash equivalents | -22,561 |
| Cash, cash equivalents and restricted cash at beginning of period | 30,711 |
| Cash, cash equivalents and restricted cash at end of period | 8,150 |
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)